(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
He suddenly couldn't speak in space. NASA astronaut says his medical scare remains a mystery - 2Palestinians tell BBC they were sexually abused in Israeli prisons
- 3They died 'doing what they loved': The stories of workers in their 80s who died on the job
- 42024 Watch Gathering: The Best Watches of the Year
- 5Defense Minister Katz moves to extend IDF service to 36 months
- REWE launches seventh Pick&Go test store in Hanover
- Phonetic Associations: A Survey of \Interfacing Worldwide People group\ Language Trade Application
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Well known Travel Booking Locales: What's Your Pick?
- SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- Trump signs a law returning whole milk to school lunches
- The architect of Iran’s military survival remains defiant
- What is IDF's view on pontential long-term occupation of southern Lebanon?
